Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel.

BACKGROUND

The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are useful prognostic indicators in various cancer types. This study assessed the utility of the mGPS and PNI in predicting survival in men with castration-resistant prostate cancer treated with cabazitaxel.

METHODS

This retrospective cohort study analyzed data on patients who received cabazitaxel for castration-resistant prostate cancer between September 2014 and March 2022. The mGPS was scored on a scale of 0-2 points based on the albumin and C-reactive protein (CRP) levels. PNI was calculated using the albumin level and lymphocyte count. The effect of the mGPS and PNI on survival was assessed using the log-rank test and Cox regression.

RESULTS

A total of 215 patients were included in the analysis, of whom 103 (47.9%), 64 (29.8%), and 48 (22.3%) had an mGPS of 0, 1, and 2 points, respectively. The median PNI was 42.2 (interquartile range [IQR]: 38.8-45.9). In a risk model using hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and mGPS, the median survival was 19, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively. In a risk model using ALP, LDH, and PNI, the overall survival was 18, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively.

CONCLUSION

The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.